Question Title

* 1. What is your email address?

Question Title

* 2. How many years have you been a practicing Interventional Cardiologist?

Question Title

* 3. Which best describes the organization for which you predominantly work?:

Question Title

* 4. Regarding use of Fractional Flow reserve (FFR) or non-hyperemic pressure ratios (NHPR) - e.g. iFR, RFR, DFR, - what do you see as the main barrier to operator uptake? Please rank 1-5, with ‘1’ being the highest barrier.

Question Title

* 5. In your primary cath lab(s), what platforms are available to you? Select all that apply.

Question Title

* 6. What factors shaped your preferences for particular platforms?

Question Title

* 7. Approximately how often do you get pressure wire drift (≥ 0.03 units) with measurements?

Question Title

* 8. Do you repeat the measurement if you get pressure wire drift ≥ 0.03?

Question Title

* 9. Does getting pressure wire drift make you less likely to use pressure wires in general in the future?

Question Title

* 10. Assume a new method existed to measure FFR or a NHPR with no change in hardware/capital equipment in your cath lab, wherein your procedural steps were reduced in half, time was reduced by at least 30%, and you could guarantee no drift would occur, would you measure FFR/NHPR in a higher % of cases?

Question Title

* 11. Assume a new method existed to measure FFR or NHPR with no change in hardware/capital equipment wherein your steps were reduced in half, time was reduced by at least 30%, and you could guarantee no drift would occur. If that method was only available using a particular platform — what is the likelihood that you would select that platform over the other options?

Question Title

* 12. Assume your primary cath lab had three different coronary physiology platforms available to you (e.g., Abbott, Phillips, and Boston Scientific) — and once again, assume a new method existed to measure FFR or NHPR with no change in hardware/capital equipment in your cath lab, wherein your steps were reduced in half, time was reduced by at least 30%, and you could guarantee no drift would occur— and that method was only available using a particular platform, which of the following would best represent your mindset?

Question Title

* 13. Assume a new method existed to measure FFR or NHPR with no change in hardware/capital equipment in your cath lab, wherein your steps were reduced in half, time was reduced by at least 30%, and you could guarantee no drift would occur — how likely would this motivate you to ask your cath lab manager to purchase this upgrade to your current physiology system?

Question Title

* 14. Assume a new method existed to measure FFR or NHPR with no change in hardware/capital equipment in your cath lab, wherein your steps were reduced in half, time was reduced by at least 30%, and you could guarantee no drift would occur — and that method was only available using a particular platform that your cath lab did not have — how likely would this motivate you to ask your cath lab manager to purchase this new physiology system?

Question Title

* 15. Do you have an angiography-guided coronary physiology platform (e.g. CathWorks) available in your cath lab?

Question Title

* 16. If Yes, what % of the time do you use angiography-guided coronary physiology (as opposed to wire-based physiology)?

Question Title

* 17. How satisfied are you with your angiography-guided coronary physiology system, scale of 1-5 (1 not satisfied, 5 very satisfied)?

Question Title

* 18. Angiography-based FFR systems require 3 orthogonal views (30 degrees apart) of the entire coronary vessel without panning, with good opacification and without overlap of other vessels being interrogated. What % of cases do you think this is achievable in?

Question Title

* 19. By submitting this survey, you are hereby accepting the terms and conditions set forth herein. If you do not agree, please do not complete the survey. Any information you voluntarily disclose to Stallion RPG, Inc. (the “Company”) in this survey (the “Respondent Data”) will be used for research purposes, content or advertising, and/or to help direct Company activities (the “Purpose”). The Company may share Respondent Data (excluding your name and email address) with third parties in furtherance of the Purpose. Furthermore, you expressly consent to receive communications from or on behalf of the Company, using all contact information you provide to us. This express consent applies to each email address or telephone number that you provide to the Company now or in the future and permits such communication including the opportunity to receive communications relating to future opportunities to participate in studies, tests, preclinical and/or clinical trials conducted by or on behalf of the Stallion RPG. You may opt-out of any communications at any time.

T